Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2014. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to a specific transaction notification and does not contain financial statements or performance metrics.
Material Changes
The filing reports a specific increase in the notional allocation of GSK American Depositary Shares (ADSs) on October 24, 2014. This change resulted from the revaluation of the cash element of a notional investment held within the GSK 401K plan. The transaction involved Dr K Slaoui (a connected person of Dr M Slaoui) and consisted of 4 ADSs at a price of $45.79 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction disclosed.
Key Facts for Investor Verification
- Transaction Date: October 24, 2014.
- Connected Person: Dr K Slaoui (Connected person of Dr M Slaoui).
- Transaction Type: Increase in notional allocation of ADSs via GSK 401K plan revaluation.
- Volume: 4 ADSs.
- Price: $45.79 per ADS.
- Reporting Date: October 27, 2014.